(Q37013124)

17 August 2017

title

Pathogen inactivation: making decisions about new technologies. Report of a consensus conference (English)

1 reference

17 August 2017

Jeffrey S Hoch

6

0 references

author name string

Harvey G Klein

1

1 reference

17 August 2017

David Anderson

2

1 reference

17 August 2017

Marie-Josée Bernardi

3

1 reference

17 August 2017

Ritchard Cable

4

1 reference

17 August 2017

William Carey

5

1 reference

17 August 2017

Nancy Robitaille

7

1 reference

17 August 2017

Marco L A Sivilotti

8

1 reference

17 August 2017

Fiona Smaill

9

1 reference

17 August 2017

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

47

1 reference

17 August 2017

issue

12

1 reference

17 August 2017

page(s)

2338-2347

1 reference

Reducing the risk of infection from plasma products: specific preventative strategies

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Protecting the blood supply from emerging pathogens: the role of pathogen inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Pathogen inactivation techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Transfusion-transmitted infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Single-donor platelets reduce the risk of septic platelet transfusion reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Threats to blood safety posed by emerging protozoan pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

The development of West Nile virus safety policies by Canadian blood services: guiding principles and a comparison between Canada and the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Serious hazards of transfusion: a decade of hemovigilance in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Emerging infectious diseases that threaten the blood supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

The precautionary principle and emerging biologic risks: lessons from human immunodeficiency virus in blood products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

New technology for transfusion safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Hepatitis B virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Neonatal and pediatric posttransfusion hepatitis C: a look back and a look forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Medicines regulation and the pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

The regulatory pendulum in transfusion medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Canadian drug regulatory framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

The Canadian blood donor health assessment questionnaire: lessons from history, application of cognitive science principles, and recommendations for change

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Economics of pathogen inactivation technology for platelet concentrates in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Economic analyses of blood safety and transfusion medicine interventions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

Pharmaco-economics of blood transfusion safety: review of the available evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

The rationale for pathogen-inactivation treatment of blood components.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

21 January 2018

Prion reduction filters.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2007.01512.X

10.1111/J.1537-2995.2007.01512.X

21 January 2018

Identifiers

DOI

1 reference

release_tkd3sowtizbdvnqaivlmufqs3i

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tkd3sowtizbdvnqaivlmufqs3i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference